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 1 
Abstract 1 
Background: Breast cancer is the most common type of cancer in women 2 
worldwide. The benefits of chemotherapy vary depending on the treatment 3 
regimen used and the characteristic of the tumour. However, adverse drugs 4 
reactions (ADRs) associated with chemotherapeutic agents can cause dose 5 
delays or reductions; thereby, affecting the treatment outcomes. 6 
Objective To explore ADRs of chemotherapeutic agents used to treat breast 7 
cancer from the patients’ perspective. 8 
Methods: A total of 110 threads form nine online discussion forums were 9 
evaluated. They were exported into Nvivo for Mac where content analysis was 10 
applied. Threads were read carefully to observe emerging patterns which were 11 
then coded into subthemes and grouped into main themes. 12 
Results: The participants characteristics on online discussion forums were often 13 
missing. 411 participants experienced 473 ADRs that were mainly associated 14 
with the nervous and immune systems. The forums’ analysis yielded three main 15 
themes: patient-patient advice, self-medication and lifestyle changes. 16 
Conclusion: Online discussion forums proposed valued source of data on ADRs 17 
associated with chemotherapeutic agents and overall patients’ experience with 18 
cancer. The ADRs experienced by patients changed their priorities and the way 19 
the dealt with the disease. Therefore, healthcare professionals must consider the 20 
 2 
patients’ experience and attitudes towards cancer when designing a treatment 21 
plan. This can be established by increasing communication between healthcare 22 
professionals and patients. 23 
 24 
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 3 
Introduction 28 
Breast cancer is a heterogeneous disease that is characterised by carcinoma 29 
formation within tissues of the breast and can be categorised in multiple ways 30 
based on; clinical features, expression of tumour markers and histologic type and 31 
is the one of the most common types of cancer. In 2015, the UK statistic for new 32 
cases of invasive breast cancer was estimated at 55,122 [1].  33 
Health-related quality of life (QOL) is an important outcome of chemotherapy 34 
among breast cancer patients. Many of the adverse drug reactions (ADRs) 35 
experienced by breast cancer patients as a result of chemotherapy can have a 36 
negative effect on the QOL during treatment and disease-free survival [2, 3].  37 
Despite the increasing number of patients taking chemotherapy each year, there 38 
are no sufficient studies that look at the patients’ perspective on ADRs associated 39 
with chemotherapeutic agents. Online discussion forums’ use for reporting ADRs 40 
has increased markedly over the last few years with 90% of adults using the 41 
Internet [4]. Subsequently, online discussions forums provide a rich source of 42 
data regarding patients’ experience as they deliver open and honest discussions 43 
[5]. Only two studies have assessed online discussion forums providing 44 
emotional support to breast cancer patients [6, 7], with no studies focusing on 45 
issues associated with anticancer treatment or patients’ QOL.  46 
 4 
The purpose of the study was to investigate  ADRs associated with chemotherapy 47 
used among breast cancer patients. 48 
 49 
Methods 50 
Study design 51 
A retrospective qualitative analysis of online discussion forums was conducted in 52 
order to explore breast cancer patients’ perspectives of ADRs associated with 53 
chemotherapeutic agents. The research comprised an inductive approach, 54 
whereby observations were first made followed by the development of theories 55 
based on patterns that emerged from the observations [8]. Furthermore, the study 56 
involved observations of individuals in situ and was therefore classified as 57 
ethnographic [9]. During data collection, categories for interpretation were 58 
created for analysis, allowing the creation of themes and sub-themes within the 59 
study [10]. As the research carried out was from direct, first-hand observations of 60 
data from online sources available to other observers, which could be tested by 61 
other researchers for validity, the study was empirical [11]. 62 
 63 
Data Collection 64 
An Internet search of widely available search engines (e.g. Google, Bing and 65 
Yahoo) was conducted to discover online forums. ADRs caused by various 66 
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chemotherapeutic drugs and chemotherapeutic drug combinations used to treat 67 
primary and secondary breast cancer were discussed publicly. Keywords used 68 
were ‘side effects’ OR ‘adverse drug reactions’ OR ‘adverse drug events’ OR 69 
‘discontinuation’ AND ‘breast cancer’, to identify forums with threads referring to 70 
ADRs encountered during or after breast cancer treatment. The search returned 71 
approximately 987,000 results and the first 10 pages were inspected for relevant 72 
websites. 73 
After inspecting multiple websites, the most relevant nine forums were selected 74 
and were: csn.cancer.org, breastcancercare.org, community.macmillan.org.uk, 75 
cancerresearchuk.org, stupidcancer.org, HealingWell.com, 76 
cancercompass.com, breastcancer.org and HER2support.org (Table 1). The 77 
forums did not require membership to view the content and were directly 78 
accessible. Internal searches were conducted on each of the nine forums for 79 
discussion threads regarding ADRs of chemotherapeutic agents used to treat 80 
breast cancer. Keywords used in the internal search were the specific drugs used 81 
to treat primary or secondary breast cancer: ‘breast cancer’ AND ‘adverse drug 82 
reactions’ or ‘adverse drug events’ or ‘side effects or discontinuation’ AND 83 
‘cyclophosphamide’ or ‘fluorouracil’ or ‘epirubicin’ or ‘paclitaxel’ or ‘doxorubicin’ 84 
or ‘docetaxel’. The resulting threads were sorted by the date of the most recent 85 
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post. The first thirty threads were reviewed and based on the inclusion and 86 
exclusion criteria some were removed. 87 
Inclusion criteria were created based on the National Institute for Health and 88 
Clnical Excellence (NICE) guidelines for the chemotherapeutic treatment of 89 
breast cancer in the UK [12] and on the National Comprehensive Cancer Network 90 
(NCCN) guidelines for the chemotherapeutic treatment of breast cancer in the US 91 
[13]. Metastatic and recurrent cancer threads were excluded, along with threads 92 
not written by the cancer patients themselves. After examination, 107 of the total 93 
of 164 threads over the nine forums were found relevant (Table 1).  94 
Data collection took place in May 2018 and threads retrieved were created by 95 
users from 2004 until March 2018. In order to maintain the flow of the posts from 96 
individual users, including the time and date posted, the threads collected were 97 
saved as PDF files. This preserved the format of the discussion as viewed on the 98 
websites. 99 
 100 
Table 1. Details of forums included in the study 101 
FN Forum name 
Number of 
threads 
Pages 
analysed 
Number of 
members 
Year(s) 
posted 
F1 Breast Cancer Care 18 57 81 2017 
F2 Breast Cancer Org 22 44 45 2010-2017 
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F3 Breast Cancer Topic 25 112 139 2008-2017 
F4 Cancer Research UK 19 42 40 2009-2017 
F5 Cancer Survival Network 6 47 66 2009-2017 
F6 
Macmillan Cancer 
Compass 
3 10 8 2004-2008 
F7 Healing Well 11 25 28 2004-2008 
F8 Stupid Cancer Community 3 6 4 2017 
 Total 107 343 411  
FN: Forum number 102 
 103 
Data Analysis 104 
Conventional thematic analysis was used for the interpretational meaning of the 105 
textual data found within the online threads (Figure 1). The technique specifically 106 
requires the generation of coding categories derived directly from the text data 107 
during analysis, as the themes are not predetermined [14, 15]. Computer-108 
assisted qualitative data analysis software was used to analyse the material for 109 
emerging patterns. In this study, a collection of 110 threads from online breast 110 
cancer discussion fora were saved as PDF files and imported into Nvivo Pro 11 111 
software. Nvivo contains the necessary tools for investigating patterns in textual 112 
data [16, 17]. 113 
 8 
All threads were analysed by another researcher (SA) following the inclusion and 114 
exclusion criteria to validate the outcomes. Data was analysed over a five-month 115 
period, between January and May 2018, each thread was read and then re-read 116 
line by line to familiarise the researcher with the content of the discussion. 117 
Concepts which could be coded into themes were searched for in the text. The 118 
unit coded for analysis may have been a word, sentence or paragraph. To ensure 119 
correct codification the context from the entire post of the user was considered. 120 
When the text was analysed and a new topic emerged, a new category was 121 
created for the data to be coded into. The categories were organised into themes 122 
and sub-themes to identify any recurring patterns. Threads that had already been 123 
coded were re-read to identify any comments containing the new topics in case 124 
they had been previously missed. Continually inspecting the raw data and coded 125 
themes maintained consistency within the analysis. 126 
The end point of the study was indicated when saturation was reached and no 127 
new themes emerged from the text as all discussion topics had been exposed. 128 
Four main themes were identified through thematic content analysis relating to 129 
the demography, chemotherapeutic treatment plan, toxicity and patient 130 
perception and advice regarding chemotherapeutic treatment.  131 
 132 
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 133 
Figure 1. Example of codification and themes created in content analysis 134 
 135 
Data Validation 136 
Analysis of the data was completed with as little bias and preconception as 137 
possible in order to maintain an open attitude towards the hypothesis of the 138 
results. Many of the ADRs reported specific to the chemotherapy within the online 139 
forums had been previously discovered in clinical studies [18, 19]. Therefore, 140 
ADRs experienced and reported in online forums could be authenticated through 141 
the comparison of various scientific journal articles. Moreover, themes and sub-142 
themes that emerged and were related to patients’ perceptions and experiences 143 
of their treatment were validated internally by two researchers from the team and 144 
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externally by comparing them to outcomes of previous literature and medical 145 
reports.  146 
 147 
Ethical Considerations 148 
This was an observational study where all data collected had already been 149 
published on the online forums under usernames to create anonymity within the 150 
thread with no interference from the research team. Additionally, any identifying 151 
features for example real names were removed from the study in order to protect 152 
the identity of the users. During the coding process, all usernames were ignored 153 
and not referred to when citing quotes from individuals in the results. The URL 154 
addresses of the threads were anonymised to make user identification more 155 
difficult. This research was approved by Bournemouth University ethics 156 
committee and followed the Declaration of Helsinki (no data was shared outside 157 
of the study). 158 
 159 
RESULTS 160 
A total of 574 (139.7%) ADRs were reported by 411 patients (Table 2). The ADRs 161 
reported affected nine systems: nervous (n = 213), immune (n = 120), skeletal (n 162 
= 59), infectious (n = 29), cardiovascular (n = 17), skin (n = 14), endocrine (n = 163 
11), ENT (n = 7) and respiratory (n = 3). 164 
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 165 
Table 2. ADRs reported by the patients 166 
Adverse effect Drug/combination N(%) 
Nervous system (n = 213) 
Neuropathy 
AC (n = 25), FEC (n = 10), paclitaxel (n = 20), 
docetaxel (n = 6), TC (n = 3),  
64 (15.6%) 
Fatigue 
"AC (n = 8), FEC (n = 16), paclitaxel (n = 4), 
docetaxel (n = 1), TC (n = 8)" 
37 (9%) 
Change in taste 
AC (n = 16), EC (n = 2), FEC (n = 5), paclitaxel (n = 
6), docetaxel (n = 3), TC (n = 5) 
37 (9%) 
Dizziness 
EC (n = 5), FEC (n= 9), paclitaxel (n = 1), docetaxel 
(n = 1) 
16 (3.89%) 
Memory loss 
AC (n = 3), EC (n = 1), FEC (n = 5), paclitaxel (n = 
1), docetaxel (n = 2), TC (n = 3) 
15 (3.65%) 
Insomnia 
AC (n = 2), FEC (n = 3), paclitaxel (n = 4), docetaxel 
(n = 1) 
10 (2.43%) 
Headache A (n = 1), AC (n = 6), FEC (n = 1) 8 (1.95%) 
Loss of appetite AC (n = 4), paclitaxel (n = 1), docetaxel (n = 1) 6 (1.46%) 
Anxiety FEC 4 (0.97%) 
Dry mouth AC (n = 3), FEC (n = 1) 4 (0.97%) 
"Abdominal and 
bowel pain" 
"AC (n = 1), paclitaxel (n = 1), FEC (n = 2)" 4 (0.97%) 
Hypothermia AC 3 (0.73%) 
Fever AC (n =1), paclitaxel (n = 1) 2 (0.49%) 
Paranoia FEC 1 (0.24%) 
Weakness AC 1 (0.24%) 
Mood swings FEC 1 (0.24%) 
Immune system (n = 120) 
Alopecia 
A (n = 2), AC (n = 30),EC (n = 5), FEC (n = 31), 
Paclitaxel (n = 18), docetaxel (n = 3), TC (n = 17) 
106 (25.8%) 
Allergic reactions AC (n = 2), paclitaxel (n = 3), docetaxel (n = 4) 9 (2.19%) 
Hair thining FEC (n = 2), paclitaxel (n = 2), docetaxel (n = 1) 5 (1.21%) 
GIT (n = 101) 
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Nausea 
A (n = 1), AC (n = 29), EC (n = 1), FEC (n = 23), 
Paclitaxel (n = 5), docetaxel (n = 1), TC (n = 5) 
65 (15.8%) 
Vomiting AC (n = 3), FEC (n = 3), paclitaxel (n =3) 9 (2.19%) 
Constipation AC (n = 6), FEC (n = 1), docetaxel (n = 1) 8 (1.95%) 
Diarrhoea FEC (n = 3), paclitaxel (n = 2) 5 (1.22%) 
Heartburn AC (n = 3), FEC (n = 1), paclitaxel (n = 1) 5 (1.22%) 
Indigestion FEC (n = 4), docetaxel (n = 1) 5 (1.22%) 
Sickness "FEC (n = 2), paclitaxel (n = 1), docetaxel (n = 1)" 4 (0.97%) 
Muscles, joints and bones (n = 59) 
Myalgia 
"AC (n = 8), FEC (n = 5), Paclitaxel (n = 9), 
docetaxel (n = 3), TC (n = 1)" 
26 (6.32%) 
Joint pain 
AC (n = 3), FEC (n = 8), paclitaxel (n = 6), docetaxel 
(n = 3) 
20 (4.87%) 
Bone pain AC (n = 3), paclitaxel (n = 1), docetaxel (n = 4) 8 (1.95%) 
"Pain in knees, legs 
and feet" 
AC (n = 1), paclitaxel (n = 4) 5 (1.22%) 
Infection (n = 29) 
Mouth ulcer 
A (n = 2), AC (n = 5), FEC (n = 1), paclitaxel (n = 2), 
docetaxel (n = 2), TC (n = 1) 
13 (3.16%) 
Flu-like symptoms 
AC (n = 7), FEC (n = 1), paclitaxel (n = 2), TC (n = 
2) 
12 (2.92%) 
Infection FEC (n= 2), docetaxel (n = 1) 3 (0.73%) 
Oral thrush FEC 1 (0.24%) 
Cardiovascular (n = 17) 
Low RBC count FEC (n = 1), T (n = 1) 2 (0.49%) 
Low neutrophil count AC (n = 1), FEC (n = 1), T (n = 1) 3 (0.73%) 
Chest pain AC 2 (0.49%) 
Cardiomyopathy A (n = 1), AC (n = 1) 1 (0.24%) 
CHF A 1 (0.24%) 
Hypertension docetaxel 1 (0.24%) 
Fluid retention 
FEC (n = 4), paclitaxel (n = 1), docetaxel (n = 1), TC 
(n = 1) 
7 (1.7%) 
Skin (n = 14) 
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Dry skin 
A (n = 1), AC (n = 2), paclitaxel (n = 1), docetaxel (n 
= 1) 
5 (1.22%) 
Rash FEC (n = 1), paclitaxel (n = 1) 2 (0.49%) 
Endocrine (n = 11) 
Watery eyes AC (n = 3), FEC (n = 3), docetaxel (n = 1), TC (n =1) 8 (1.95%) 
Weight gain A (n = 1), paclitaxel (n = 1) 2 (0.49%) 
Weight loss FEC 1 (0.24%) 
ENT (n = 7) 
Hearing loss FEC 4 (0.97%) 
Change in smell AC 2 (0.49%) 
Nose bleeding FEC 1 (0.24%) 
Respiratory (n = 3) 
Breathing problems AC (n = 2), paclitaxel (n = 1) 3 (0.73%) 
A: Adriamycin; AC: Adriamycin, cyclophosphamide; EC: epirubicin, 167 
cyclophosphamide; FEC: Fluorouracil, epirubicin, cyclophosphamide; TC: 168 
docetaxel, cyclophosphamide; T: docetaxel 169 
 170 
 171 
Characteristics of the reported adverse effects  172 
Nervous system 173 
 17 categories emerged under nervous system toxicity being: Neuropathy, 174 
fatigue, change in taste, dizziness, memory loss, loss of taste, insomnia, 175 
headache, loss of appetite, anxiety, dry mouth, abdominal and bowel pain, 176 
hypothermia, fever, paranoia, weakness and mood swings. The most prevalent 177 
categories were neuropathy, fatigue, change in taste, dizziness and memory loss, 178 
and were reported by 64 (15.6%), 37 (9%), 37 (9%), 16 (3.89%) and 15 (3.89%) 179 
respectively. This was followed by insomnia, headache and loss of appetite that 180 
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were reported by 10 (2.43%), 8 (1.95%) and 6 (1.46%) members respectively. 181 
Only 4 (0.97%) reported each of anxiety, dry mouth and abdominal pain. In 182 
addition, 1-3 members reported hypothermia, fever, paranoia, weakness and 183 
mood swings. 184 
Neuropathy was mainly associated with the use of Adriamycin/cyclophosphamide 185 
(AC) (n = 25) or paclitaxel (n = 20) yet was encountered with other regimens 186 
including fluorouracil/epirubicin/cyclophosphamide (FEC), docetaxel and 187 
docetaxel/cyclophosphamide (TC). Neuropathy was described as worst with 188 
docetaxel than other drugs. Symptoms comprised numbness in fingertips, 189 
numbness or tingling in the feet, legs from the knee down, toes, face and 190 
fingertips. Facial numbness was described as ‘rare’ and ‘unusual’ whereas other 191 
types were more common. Additional symptoms associated with neuropathy 192 
included getting cold shivers out of a sudden, feeling of pins and needles in feet 193 
and constantly dropping things. Members described that symptoms improve ‘as 194 
the cycle goes on’. Neuropathy stopped either straight after completion of 195 
treatment or 4-5 weeks after completion.  196 
Fatigue was associated with the use of AC, FEC, paclitaxel, docetaxel and TC. 197 
Fatigue was described as cumulative over the treatment and its intensity of 198 
fatigue varied depending on the regimen. With AC, FEC, TC and docetaxel, 199 
fatigue was described as mildly cumulative over the treatment duration, tiring, 200 
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affecting productivity, but ‘not so bad’. It started wearing off after the last infusion. 201 
Nonetheless with paclitaxel, fatigue was intense, felt the entire time and could 202 
last for years afterwards (up to five years).  203 
Change in taste and loss of taste were associated with the use of AC, 204 
epirubicin/cyclophosphamide (EC), FEC, paclitaxel, Docetaxel and TC. Change 205 
in taste comprised several categories being ‘awful chemical taste’, ‘bad’, 206 
‘’constantly horrible’, ‘salty’, ‘strange’, ‘metallic’, ‘nasty’, ‘unavoidable’, ‘loss of 207 
taste’. The change of taste was experienced at days 3-5 of each cycle and the 208 
taste buds were back normal 24 hours after the end of each infusion. In some 209 
cases, the change in taste lasted up to three days after the infusion. 210 
Dizziness was associated EC, FEC, paclitaxel and docetaxel. Members 211 
experienced dizziness, spinning, light-headedness, fuzzy-headedness and loss 212 
of balance. Dizziness was encountered when in bed and when in walking. 213 
Moreover, 15 (3.65%) members reported memory loss that was associated with 214 
the use of AC, EC, FEC, paclitaxel, docetaxel and TC. Memory loss was labelled 215 
as ‘chemo brain’ where patients reported to forget everything and was associated 216 
with ‘lack of concentration’. 217 
Insomnia, headache and loss of appetite were associated with Adriamycin (A), 218 
AC, FEC, paclitaxel and docetaxel. Patients felt sleepy yet were not able to fall 219 
asleep. Insomnia was worst with paclitaxel than the other derivatives. Headaches 220 
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were attributed to lack of sleep yet varied in duration and lasted up to four hours. 221 
Moreover, members reported loss of appetite where they could not eat anything 222 
all day. 223 
Anxiety, dry mouth and abdominal pain were linked to FEC, AC and paclitaxel. 224 
Anxiety was described as ‘terrible’, ‘chipping constantly’ and often led to 225 
hospitalisation. Members also reported dry mouth that lasted up to 8 months after 226 
chemotherapy. In additional, abdominal pain was designated as severe and 227 
lasting for a long time.  228 
Hypothermia, fever, paranoia, weakness and mood swings were less frequent 229 
effects experienced by members who had taken AC, FEC and paclitaxel. 230 
Members recommended checking temperature twice a day to monitor decrease 231 
or increase in temperature. Moreover, weakness and worrying about the 232 
condition were associated with paranoia and mood swings. 233 
 234 
Immune system 235 
Three categories emerged under immune system toxicity including alopecia, hair 236 
thinning and allergic reactions contributing to 106 (25.8%), 5 (1.21%) and 9 237 
(2.19%) respectively. 238 
Alopecia was the top reported ADR. It consisted of three subcategories including 239 
head hair loss (n = 83), eyebrow and eyelashes loss (n = 23). Hair loss was 240 
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described as an ‘unpleasant experience’, ‘not fun’, ‘unsettling’, ‘traumatic’ and 241 
‘the worst ADR of treatment’. Members described losing either half or whole of 242 
their eyebrows and lashes. Hair loss was encountered at various intervals during 243 
the treatment being within 14, 16 or 21 days. The main two regimens associated 244 
with alopecia were FEC and AC that had been experienced by 31 and 30 users 245 
respectively. Other derivatives associated with alopecia were A, EC, paclitaxel, 246 
docetaxel and TC. Users reported the loss of mainly the head hair followed by 247 
eyebrow/ eyelashes and facial hair. Few members experienced hair thinning (n = 248 
5) instead of alopecia and was mainly attributed to FEC, paclitaxel and docetaxel. 249 
After stopping the aforementioned regimen, users experienced the regrowth of 250 
hair but it was described as a slow growth, with super thin hair and ‘with severe 251 
chemo curls’. In other instances, the regrown hair was white or ash looking and 252 
thicker: 253 
 254 
My hair also started off as pure white fuzz, but it’s slowly starting to fill in darker. 255 
I can’t tell what colour it is yet, very ash looking (yeah. Light & dark grey). But 256 
honestly it is getting thicker daily and I am happy to just have some hair up 257 
there. (Thread 97, page 8) 258 
 259 
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In other cases, the hair regrowth was described as ‘white’, ‘whitish non-colour’, 260 
‘dark brown hair’ or ‘very grey’. On the other hand, eyelashes and eyebrows 261 
regrowth varied between users. In some cases, it was thinner and in others it was 262 
thicker and longer. The recovery of hair took between 8 -12 weeks after 263 
treatment.  264 
Allergic reactions were associated with AC (n = 2),paclitaxel (n = 3) or docetaxel 265 
(n = 4). The allergic reaction varied between the three medicines. Allergic 266 
reactions resulting from AC use and affected the eyes, hands, feet and lower 267 
legs. Moreover, allergic reactions due to paclitaxel affected the face occurred 268 
during the infusion. With docetaxel, reactions were intense and encountered in 269 
every treatment with bright red face and tightness of chest. In the four cases 270 
encountered with docetaxel, members reported that the nurses had been quick 271 
in stopping the reaction.  272 
 273 
 274 
Gastrointestinal 275 
Seven categories emerged under GIT toxicity being nausea, vomiting, 276 
constipation, diarrhoea, heartburn, indigestion and ‘sickness’. The 277 
aforementioned categories contributed to 65 (15.8%), 9 (2.19%), 8 (1.95%), 5 278 
(1.22%), 5 (1.22%), 5 (1.22%) and 4 (0.97%) respectively. 279 
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Nausea associated with A, AC, EC, FEC, paclitaxel, docetaxel and TC. It was 280 
‘very tiring’, ‘bad’ and ‘uncontrollable’. Though it was highly prevalent in AC (n = 281 
29) and FEC (n = 23) regimens, it was worse with paclitaxel. Vomiting was 282 
associated with AC, FEC and paclitaxel. It lasted up to two days and in one 283 
instance led to hospitalisation. Constipation was associated with AC, FEC and 284 
docetaxel, was described as awful and lasted up to one week. Constipation was 285 
further described as the most difficult part and not cured all the time by medicines. 286 
Likewise, diarrhoea was not controlled by medicines and was associated with 287 
FEC and paclitaxel. Diarrhoea was described as one of the worst effects and 288 
lasted up to 4 weeks after the chemo finished. Heartburn, indigestion and 289 
‘sickness’ were described as terrible yet tolerable and were associated with AC, 290 
FEC, paclitaxel and docetaxel. ‘Sickness’ occurred straight after the infusion but 291 
was controlled by combination of medicines. 292 
 293 
Muscle, joints and bones  294 
Four categories emerged under muscle, joints and bones toxicity and included 295 
myalgia, joint pain, bone pain and pain in knees, legs and feet. The 296 
aforementioned categories contributed to 26 (6.32%), 20 (4.87%), 8 (1.95%) and 297 
5 (1.22%) respectively. Members reported aches in muscles and bones as well 298 
as stiffness. At one instance, the pain was described as ‘debilitating at times’, 299 
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‘horrible’, ‘tremendous’ and ‘being hit with sacks of flour’. Members also described 300 
joint pain as ‘awful’, ‘accumulative’ and mainly ‘in the legs and feet’. Pain was 301 
relieved by ibuprofen, paracetamol or loratadine and stopped within months of 302 
completion of the treatment.  303 
 304 
Infection  305 
A total of four categories were encountered and were mouth ulcers, flu-like 306 
symptoms, infection and oral thrush, and were reported by 13 (3.16%), 12 307 
(2.92%), 3 (0.73%) and 1 (0.24%) respectively. Severe mouth sores and ulcers 308 
were experienced throughout the treatment and after the treatment. The mouth 309 
sores were described as severe and not always relieved by mouthwash, ice chips 310 
or popsicles. Infection was reported to be similar to flu. Flu-like symptoms 311 
comprised high temperature, body aches, body weakness, nasal drip, strange 312 
cough and in one instance led to hospitalisation. In other cases, members 313 
reported shingles that was secondary to low white blood cells (WBC) counts. 314 
 315 
Cardiovascular  316 
Cardiovascular toxicity comprised seven categories being fluid retention, low 317 
neutrophil count, low red blood cells (RBC) count, chest pain, cardiomyopathy, 318 
congestive heart failure (CHF) and hypertension that were stated by 7 (1.7%), 3 319 
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(0.73%), 2 (0.49%), 2 (0.49%), 1 (0.24%), 2 (0.49%) and 1 (0.24%) members 320 
respectively. Fluid retention was experienced where members reported severely 321 
swollen ankles. In one instance, the retention cleared 10 days after the treatment. 322 
Fluid retention associated with docetaxel resulted in severe hypertension with 323 
‘extreme pressure in the head’. Members also stated their experience with chest 324 
discomfort, low blood pressure, rapid heartbeats. Moreover, neutrophil count was 325 
very low that the patient ended up with a couple of blood transfusions and few 326 
hospital stays. Cardiomyopathy and CHF were associated with A’s use that had 327 
been described as a ‘wicked drug’. One member reported: 328 
‘I just found out I have congestive heart failure caused from receiving 329 
Adriamycin 10 years ago- never had muga or echo testing done before or after 330 
and now looking at having to get a pacemaker for the damage it caused.’ 331 
(Thread 2, page 8) 332 
 333 
 334 
Skin  335 
Skin toxicity had two categories being dry skin and rash that were informed by 5 336 
(1.22%) and 2 (0.49%) members respectively. Members reported dry skin 337 
throughout their whole body during the treatment. Skin itching and skin flushing 338 
were experienced where members experienced itching without numbness. Skin 339 
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rash was experienced in the face (red), back of the hands (black) and fingers 340 
(red). The skin felt rough and sore and was cleared in one instance by 341 
doxycycline antibiotic.  Members had also experienced loss of fingernails and 342 
toenails. Members reported brittle nails that have never disappeared. Fingernails 343 
have grown back six months post chemotherapy. 344 
 345 
Endocrine 346 
Endocrine toxicity encompassed three categories being watery eyes, weight gain 347 
and weight loss that were reported by 8 (1.95%), 2 (0.49%) and 1 (0.24%) 348 
respectively. Watery eyes were described as ‘terrible’ ‘ streaming’, ‘so bad’. The 349 
watery eyes associated with docetaxel use lasted for seven years after the 350 
completion of the chemotherapy. Patients gained up to 20 lbs on paclitaxel. On 351 
the other hand, one patient lost a third half of the weight when on FEC+T. 352 
 353 
Ear, Nose and Throat  354 
Members reporting ear, nose and throat (ENT) toxicity had experienced hearing 355 
loss (n = 4), change in smell (n = 2) and nose bleeding (n = 1). Members reported 356 
block in their ear with nothing to clear them. In two of the cases, it was important 357 
to use a hear aid in each ear. Members reported bad smell at the end of each 358 
infusion or the inability to smell anything at all (even flowers of skunk). Also, 359 
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exaggerated smells were reported. Nose bleeding was reported as mild and 360 
relieved using a cream (unspecified). 361 
 362 
Respiratory  363 
Respiratory toxicity had only one category that was breathing problems 364 
associated with AC and paclitaxel. Breathing problems were experienced when 365 
patients tried to inhale deeply that caused continuous coughing. The coughing 366 
was controlled using antihistamines and disappeared at the end of the 367 
chemotherapy. Taking a deep breath was difficult for patients and felt ‘like coming 368 
out of bronchitis’. 369 
 370 
Qualitative themes emerged 371 
Theme 1: Patient-patient advice 372 
Patients recommended medicines or lifestyle modifications to other patients for 373 
various conditions including: hair loss, nail loss, nausea, peripheral neuropathy 374 
and mouth sores. 375 
For hair loss, the cold cap was recommended during chemotherapy after having 376 
a short haircut before the first session (in order to have less pressure on the 377 
roots). Other recommendations for prevention of hair loss comprised using a wide 378 
tooth comb, combing gently, washing less and using dry shampoo.  Another 379 
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recommendation was to wash the hair once a week and Paxman shampoo and 380 
conditioner.  381 
As preventive measure for nail loss different recommendations were given 382 
including: icing hands and feet, keeping the nails short, using vitamin E oil around 383 
the nails several times per day, having weekly bath salts (during paclitaxel).  384 
For nausea, it was recommended to stay hydrated, drinking lots of water before 385 
the chemotherapy and taking nausea medicines on schedule. One patient 386 
reported: 387 
 388 
Take your nausea pills like clockwork! Even if you don’t feel nauseous, don’t 389 
wait until you do feel sick, it’s harder to get it under control at least for the first 4 390 
days or so, keep a log book for your side effects and how you feel each day so 391 
when you get to round 2 etc…Drink a lot of water to help flush it out of your 392 
body. (Thread 105, page 2) 393 
 394 
Moreover, frequent eating by having lots of light snacks was recommended as a 395 
prevention for nausea. Other patients recommended taking pills on time in order 396 
to overcome nausea. 397 
For peripheral neuropathy, frozen water bottles were recommended as a 398 
preventive measure against burning hands and feet: 399 
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 400 
And I had peripheral neuropathy which caused burning pain in my hands and 401 
feet, but I found if I held frozen water bottles in my hands it helped drive the 402 
paclitaxel away from my hands and prevented the neuropathy (Thread 101, 403 
page 1) 404 
Against mouth sores, chomping ice chips during the infusion was advised as a 405 
preventive measure. Other recommendations for mouth sores included rinsing 406 
with salty water, using Biotene, seeing a dentist about a dental hygienic 407 
regimen: 408 
 409 
‘Things that have helped me so far, include Biotene for my mouth (Thread 22, 410 
page 2)’. 411 
 412 
Theme 2: Self-medication 413 
Self-treatment has emerged among patients for few conditions where patients 414 
had taken medicines or alternative approaches in order to control certain effects. 415 
For instance, vitamin B12 was suggested as a preventive measure for 416 
neuropathy: 417 
 418 
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The only thing I would change is to start taking vitamin B12 to prevent the 419 
neuropathy that started near the end of Paclitaxel. It's gone now. I still take B12 420 
(Thread 103, page 2). 421 
 422 
In addition, drinking lots of water and sucking sweets was recommended for dry 423 
mouth. For loss of taste, patients recommended drinking lots of fluid, having 424 
lemon juice and/or eating stronger tasting food: 425 
 426 
Lemon juice helps a bit (thread 99, page 2) 427 
 428 
Furthermore, patients reported using oils, creams or wax for dry skin and 429 
chapped lips. Oil was recommended either by applying it directly to the skin or 430 
putting few drops in the bath at night. Nonetheless, creams and waxes were 431 
applied directly to the skin. 432 
 433 
Theme 3: Lifestyle changes  434 
Patients reported lifestyle changes relating to diet, exercise and stress 435 
management. Patients moved to having a healthy plant-based diet, having more 436 
vegetables, fresh juices, vitamins and exercising more. Patients also reported 437 
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going on stress management programmes but had not specified the types of 438 
programmes. One patient reported: 439 
 440 
I'm trying to eat more greens, like kale, spinach, avocados, and trying (Thread 441 
102, page 5) 442 
Another patient reported: 443 
 444 
I also turned to exercise and fresh carrot juice. I believe it had a lot to do with 445 
my recovery. I believe the carrot juice help remove the toxins from my joints and 446 
the exercise definitely rebuilt the muscles around the joints. (Thread 1, page 3) 447 
 448 
 449 
DISCUSSION 450 
This study utilised online discussion forums in order to explore the ADRs 451 
experienced by breast cancer patients. The findings of the study were important 452 
in uncovering the daily experiences of patients coping with the condition (breast 453 
cancer) and their attitudes towards the condition. Our research added to the 454 
existing significant research regarding ADRs experienced by cancer patients due 455 
to chemotherapeutic agents [20-22]. The aforementioned three studies focused 456 
on quantitative data regarding ADRs experienced by hospitalised patients during 457 
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[19] or qualitative data obtained from interviews/questionnaire with patients after 458 
hospitalisation [20-22]. None of the aforementioned studies used retrospective 459 
analysis of online discussion forums. 460 
Online discussion forums data offer an advantage over interviews and 461 
questionnaires in obtaining further insight into the patients’ own attitudes towards 462 
the condition and experience within the condition. Online patient communities 463 
propose a significant source of information particularly for excluded patients in 464 
traditional research studies [23]. The increased use of online discussion forums 465 
has increased substantially with the increased use of the Internet among 466 
individuals worldwide [23]. Patients utilise the Internet in order address their 467 
condition, access advise about the condition and manage their therapy [24, 25]. 468 
To date, there are limited qualitative studies that analyse the content of online 469 
discussion forums published by breast cancer patients who had experienced 470 
ADRs as a result of their chemotherapeutic treatment regimens. On the contrary 471 
the few studies that explored qualitative breast cancer patients’ perspectives had 472 
focused on psychological distress following diagnosis [6, 26] or psychological 473 
support for patients [7].  474 
Our study was the first qualitative study that explored the perspectives and 475 
attitudes of breast cancer patients towards ADRs experienced following 476 
treatment with chemotherapeutic agents. Online discussion forums allowed 477 
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patients to express their thoughts in unrestricted manner; hence, they provided a 478 
wealth of information about the physical and psychological ADRs experienced by 479 
patients [27]. In this respect, the findings of the study showed that patients 480 
experienced numerous ADRs associated with multiple systems of which the main 481 
ones were the nervous, immune and skeletal system. In dealing with the ADRs, 482 
three main themes emerged from the study related to patient-patient advice, self-483 
medication and lifestyle changes. 484 
Patient sought advice from other patients in order to deal with their condition, 485 
chemotherapeutic regimen(s) and their associated ADRs. Patients sought 486 
knowledge and emotional support from the online discussion forums mainly to 487 
deal with anxiety, depression and stress experienced as a result of their disease 488 
[6, 7]. The knowledge acquired from online discussion forums was perceived as 489 
more valuable to the patients as it had been obtained directly from available 490 
resources and not through an authoritative, filtering agent such as a doctor or 491 
nurse [28]. This showed that the patient-doctor relationship has changed and 492 
depended on the outcomes/lifestyle of patients and that coincided with the 493 
findings on other studies [29, 30]. Hence, the Internet era changed the behaviour 494 
of patients and made them rely on personalised information from the Internet 495 
rather than seeking it from experts [30, 31]. Patients’ personalised behaviour was 496 
not only apparent in seeking advice about the condition and ways to cope with it 497 
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but also with patients’ self-prescribing and self-medicating [32, 33]. Modern 498 
patients felt more convenient in managing their own illness and medication than 499 
visiting experienced healthcare professionals. This was attributed to several 500 
reasons being: urge of self-care in the Internet era, use of personalised 501 
information, financial constraints, lack of time, lack of adequate health services, 502 
health ignorance, extensive adverts of medicines and availability of medicines 503 
outsides pharmacies [32, 34-35]. Specifically, online discussion forums were 504 
convenient for patients because they provided a tool to exchange of knowledge, 505 
advice and provide relief from the stress associated with their conditions. 506 
Individuals had the ability to post anonymously and unrestricted manner. Hence, 507 
online discussion forums were a safe place for patients to express and discuss 508 
their thoughts and emotions in an uninhibited manner [27]. 509 
 510 
Strengths and Limitations 511 
The findings of the study were extremely useful in providing in-depth information 512 
about the patients’ experience of ADRs and their behaviour towards the condition. 513 
Patients felt more freely to express themselves in an honest and non-biased 514 
manner using online discussion forums than they would do face-to-face. The use 515 
of content analysis in exploring the results was advantageous as it required no 516 
cooperation from patients. As the content analysis was applied to retrospective 517 
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data, there was not bias as experienced in interviews or surveys where 518 
participants would be prompted to achieve a specific outcome. Currently, there 519 
are limited scientific literature on qualitative studies of ADRs experienced by 520 
breast cancer patients receiving chemotherapy treatment. This study determined 521 
detailed information on the toxicities associated with the administration of 522 
chemotherapy agents. 523 
Nonetheless, several limitations were encountered in this study. As the project 524 
was retrospective in nature, there were gaps of information missing throughout 525 
the study. It was not always possible to obtain all of the information desired, for 526 
example, type of breast cancer, age, geographical location and drug dosage. 527 
However, in retrospective studies missing data is often reported as an issue. 528 
Another limitation of the study was that there had not been a way to authenticate 529 
the information claimed by patients regarding their condition and symptoms. 530 
Using online discussion forums, individuals feel invisible and thus have the 531 
courage to say things they may otherwise not [27]. Moreover, the study was 532 
limited to individuals that used the Internet discussion forums and that affected 533 
the generalisability of the results. 534 
 535 
CONCLUSION 536 
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Online discussion forums provided valuable and detailed information regarding 537 
the toxicity of chemotherapeutic agents not currently present in scientific 538 
literature. By uncovering themes related to patient experience, the online 539 
discussion forums represented important source of qualitative data additional to 540 
traditional sources of information. 541 
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